The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Newborn Screening for Congenital Adrenal Hyperplasia: Additional Steroid Profile using Liquid Chromatography-Tandem Mass Spectrometry
Abstract
Background: Neonatal screening programs for congenital adrenal hyperplasia (21-CAH) using an immunoassay for 17α-hydroxyprogesterone (17-OHP) generate a high rate of positive results attributable to physiological reasons and to cross-reactions with steroids other than 17α-OHP, especially in preterm neonates and in critically ill newborns. Methods: To increase the specificity of the screening process, we applied a liquid chromatography-tandem mass spectrometry method quantifying 17α-OHP, 11-deoxycortisol, 21-deoxycortisol, cortisol, and androstenedione. The steroids were eluted in aqueous solution containing d8-17α-OHP and d2-cortisol and quantified in multiple reaction mode. Results: Detection limit was below 1 nmol/liter, and recovery ranged from 64% (androstenedione) to 83% (cortisol). Linearity was proven within a range of 5–100 nmol/liter (cortisol, 12.5–200 nmol/liter), and total run time was 6 min. Retrospective analysis of 6151 blood samples and 50 blood samples from newborns with clinically confirmed 21-CAH, as well as prospective analysis of 1609 samples of a total of 242,500 testing positive in our routine 17-OHP immunoassay, allowed clear distinction of affected and nonaffected newborns. High levels of 21-deoxycortisol were only found in children with 21-hydroxylase deficiency. Calculating the ratio of 17α-OHP to 21-deoxycortisol divided by cortisol further increased the sensitivity of the method. Conclusion: Our liquid chromatography-tandem mass spectrometry procedure as a second-tier test can be used to reduce false-positive results of standard 21-CAH screening. The short total run time of 6 min allows for immediate reanalysis of all immunoassay results above the cutoff.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to nonclassic lipoid CAH, nonclassic SCC deficiency has been described with delayed adrenal insufficiency onset and variable gonadal effect, caused by mutations corresponding to 7-30% of retained enzyme activity.[55][56][57][58]”
From Congenital adrenal hyperplasia (2017) · cites this paper as [55]
In the citing paper
“The run times for individual samples in such assays are 6 to 12 minutes, impractical for screening large numbers of samples, but suitable for the smaller numbers subjected to a secondtier screen using the original dried blood samples (78,80).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [80]
In the citing paper
“A modified LC-MS/MS protocol used a ratio defined as the sum of 17OHP and 21-deoxycortisol levels divided by the cortisol level, and this parameter correctly identified all affected children with no false positives, for a positive predictive value of 100% (80).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [80]
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Beckett, A. H., Rowland, M., & TURNER, P. (1965) · The Lancet · doi:10.1016/s0140-6736(65)91037-8 · Cited by 16,917
Measuring agreement in method comparison studies
Bland, J. M., & Altman, D. G. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800204 · Cited by 9,619
Vogeser, M., Zachoval, R., Felbinger, T. W., Jacob, K., Radetti, G., Bona, G., Corrias, A., Cappa, M., DeSanctis, V., Lauriola, S., et al. (2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 452
Pang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392
Dewitte, K., Fierens, C., Stöckl, D., & Thienpont, L. M. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.5.799 · Cited by 356
Pang, S., Wallace, M. A., Hofman, L. F., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · PEDIATRICS · doi:10.1542/peds.81.6.866 · Cited by 302
PANG, S., HOTCHKISS, J., DRASH, A. L., LEVINE, L. S., & NEW, M. I. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-5-1003 · Cited by 293
Lacey, J. M., Minutti, C. Z., Magera, M. J., Tauscher, A. L., Casetta, B., McCann, M., Lymp, J., Hahn, S. H., Rinaldo, P., & Matern, D. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.027193 · Cited by 216
Wong, T., Shackleton, C. H., Covey, T. R., & Ellis, G. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.9.1830 · Cited by 159
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–210 of 210
Li, Z., Liang, Y., Du, C., Yu, X., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · Figshare · doi:10.6084/m9.figshare.17083925
Li, Z., Liang, Y., Du, C., Yu, X., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · Figshare · doi:10.6084/m9.figshare.17083931
A Two-Step LC-MS/MS method to differentiate 21OHD and PORD in Screen-Positive newborns
Nakatani, H., Watanabe, K., Tsuji‐Hosokawa, A., Sutani, A., Saito, Y., Kirino, S., Yamano, H., Orimoto, R., Gau, M., Yogi, A., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04573-z
Plessas-Azurduy, P., Garfinkle, J., Beltempo, M., Porraccio, C., Lapointe, A., Wazneh, L., Wutthigate, P., Spénard, S., Sbrocchi, A. M., Racine, M. M. B., et al. (2026) · Children · doi:10.3390/children13040475
Neonatal Screening for CAH in Sweden—Results of Implementing Second-Tier Testing
Engström, K., Zetterström, R. H., Wedell, A., & Nordenström, A. (2026) · International Journal of Neonatal Screening · doi:10.3390/ijns12020029 · Cited by 1
Vorontsova, M. V., Чугунов, И. С., Владимировна, К. И., Shapovalova, A. E., Максимовна, Г. А., Peterkova, V. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13758
de Hora, M. R., Hofman, P. L., Cheong, J. L. Y., Davis, P. G., Doyle, L. W., Francis, K. L., Kamlin, C. O. F., Manley, B. J., & McKinlay, C. J. D. (2026) · Journal of Perinatology · doi:10.1038/s41372-026-02764-0
Update Neugeborenenscreening: Neue Zielkrankheiten seit 2025
Fingerhut, R. (2026) · Trillium Diagnostik · doi:10.47184/td.2026.02.01
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Tuli, G., Munarin, J., Pavanello, E., & SANCTIS, L. D. (2026) · Endocrine · doi:10.1007/s12020-026-04759-5
Metadata
- Authors
- Janzen, N., Peter, M., Sander, S., Steuerwald, U., Terhardt, M., Holtkamp, U., & Sander, J.
- Affiliations
- Screening-Labor Hannover, D-30430 Hannover, Germany
- Corresponding author
- Janzen, N.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-07-01
- Volume
- 92
- Issue
- 7
- Pages
- 2581-2589
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1984703540
- Cited by
- 211
- References
- 26
- Citations by year
- 2026: 11 · 2025: 7 · 2024: 6 · 2023: 12 · 2022: 9 · 2021: 23 · 2020: 9 · 2019: 12 · 2018: 3 · 2017: 7 · 2016: 6 · 2015: 12 · 2014: 9 · 2013: 15 · 2012: 7
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, newborn screening, 17-hydroxyprogesterone, 21-deoxycortisol, 11-deoxycortisol, cortisol, androstenedione, steroid profile, false positives, immunoassay cross-reactivity, LC-MS/MS
- MeSH terms
- Adrenal Hyperplasia, Congenital, Androstenedione, Calibration, Chromatography, High Pressure Liquid, Cortodoxone, False Positive Reactions, Female, Humans, Hydrocortisone, Infant, Newborn, Infant, Premature, Male, Prospective Studies, Retrospective Studies, Reproducibility of Results, Neonatal Screening, 17-alpha-Hydroxyprogesterone, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
